Syndax Announces Participation in June Investor Conferences

5/29/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNDX alert in real time by email

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
Goldman Sachs 46^th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.

[email protected]

Tel 781.684.9827

SNDX-G

Get the next $SNDX alert in real time by email

Recent Analyst Ratings for

$SNDX

Date	Price Target	Rating	Analyst
8/5/2025	$43.00 → $56.00	Buy	BTIG Research
7/10/2025	$18.00	Buy	Goldman
10/24/2024	$37.00	Buy	UBS
6/28/2024	$37.00	Buy	Jefferies
1/31/2024	$36.00 → $23.00	Sector Outperform → Sector Perform	Scotiabank
12/22/2023	$45.00	Buy	Mizuho
10/25/2023	$29.00	Buy	BofA Securities
10/11/2023	$30.00	Buy	Goldman

More analyst ratings

Syndax Announces Participation in June Investor Conferences

5/29/25 7:00:00 AM ET

$SNDX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNDX alert in real time by email

Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
Goldman Sachs 46^th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.

[email protected]

Tel 781.684.9827

SNDX-G

Get the next $SNDX alert in real time by email

Recent Analyst Ratings for

$SNDX

Date	Price Target	Rating	Analyst
8/5/2025	$43.00 → $56.00	Buy	BTIG Research
7/10/2025	$18.00	Buy	Goldman
10/24/2024	$37.00	Buy	UBS
6/28/2024	$37.00	Buy	Jefferies
1/31/2024	$36.00 → $23.00	Sector Outperform → Sector Perform	Scotiabank
12/22/2023	$45.00	Buy	Mizuho
10/25/2023	$29.00	Buy	BofA Securities
10/11/2023	$30.00	Buy	Goldman

More analyst ratings

Syndax Announces Participation in June Investor Conferences

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$SNDX

Syndax Announces Participation in June Investor Conferences

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$SNDX

$SNDX
FDA approvals

FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

$SNDX
Press Releases

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

$SNDX
SEC Filings

SEC Form 144 filed by Syndax Pharmaceuticals Inc.

SEC Form 144 filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

$SNDX
Analyst Ratings

BTIG Research reiterated coverage on Syndax Pharmaceuticals with a new price target

Goldman initiated coverage on Syndax Pharmaceuticals with a new price target

UBS initiated coverage on Syndax Pharmaceuticals with a new price target

$SNDX
Insider Trading

Director Podlesak Dennis sold $875,100 worth of shares (57,600 units at $15.19) and exercised 57,600 shares at a strike of $7.20 (SEC Form 4)

Chief Financial Officer Goldan Keith A. acquired $10,335 worth of shares (1,226 units at $8.43), increasing direct ownership by 1% to 93,676 units (SEC Form 4)

Chief Executive Officer Metzger Michael A sold $69,953 worth of shares (7,534 units at $9.29), decreasing direct ownership by 2% to 298,661 units (SEC Form 4)

$SNDX
Insider Purchases

Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

$SNDX
Leadership Updates

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

$SNDX
Financials

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

$SNDX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

Syndax Announces Participation in June Investor Conferences

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $SNDX

Syndax Announces Participation in June Investor Conferences

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $SNDX

$SNDX FDA approvals

FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

$SNDX Press Releases

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

$SNDX SEC Filings

SEC Form 144 filed by Syndax Pharmaceuticals Inc.

SEC Form 144 filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

$SNDX Analyst Ratings

BTIG Research reiterated coverage on Syndax Pharmaceuticals with a new price target

Goldman initiated coverage on Syndax Pharmaceuticals with a new price target

UBS initiated coverage on Syndax Pharmaceuticals with a new price target

$SNDX Insider Trading

Director Podlesak Dennis sold $875,100 worth of shares (57,600 units at $15.19) and exercised 57,600 shares at a strike of $7.20 (SEC Form 4)

Chief Financial Officer Goldan Keith A. acquired $10,335 worth of shares (1,226 units at $8.43), increasing direct ownership by 1% to 93,676 units (SEC Form 4)

Chief Executive Officer Metzger Michael A sold $69,953 worth of shares (7,534 units at $9.29), decreasing direct ownership by 2% to 298,661 units (SEC Form 4)

$SNDX Insider Purchases

Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

$SNDX Leadership Updates

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

$SNDX Financials

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

$SNDX Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

Recent Analyst Ratings for
$SNDX

Recent Analyst Ratings for
$SNDX

$SNDX
FDA approvals

$SNDX
Press Releases

$SNDX
SEC Filings

$SNDX
Analyst Ratings

$SNDX
Insider Trading

$SNDX
Insider Purchases

$SNDX
Leadership Updates

$SNDX
Financials

$SNDX
Large Ownership Changes